Good morning, members of the committee.
To our invited guests, good morning, and thank you for being here.
Pursuant to Standing Order 108(2), we are involved in the study of the status of the NRU reactor and the supply of medical isotopes.
Members of the committee have been spared the presence of the chair. He is on the road, and I will be filling in for him. I didn't mean that we'd been spared the presence. We will all miss him tremendously, and I'll certainly let him know that when he returns.
We'd like to welcome, as an individual, Mr. Peter Goodhand. Welcome, Mr. Goodhand. Thank you for being here.
And we have, from Covidien, Stephen Littlejohn, vice-president, communications, pharmaceuticals division. Welcome.
As well, we have Philippe Hébert, director of sales and marketing, pharmaceuticals division, Tyco Healthcare Canada.
I recognize some who have made deputations before committee, but I will give an explanation. We allow eight to ten minutes. We invite you to make your presentations during that time. Then we begin with a seven-minute round of questions and answers from the members. We'll try to expedite that. The second round, if that's possible, is usually five minutes.
Without any further ado, Mr. Goodhand, would you like to lead off?